Welcome to our dedicated page for ZIMVIE SEC filings (Ticker: ZIMV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to locate critical details on ZimVie’s dual dental–spine operations? Each ZimVie Inc. filing layers FDA clearance updates, clinical trial milestones, and segment revenue splits across hundreds of pages. Sorting through that volume is tough, especially when you simply want to know if a new implant cleared the regulator or how surgeon adoption is trending.
Stock Titan solves that problem. Our AI reads every ZimVie quarterly earnings report 10-Q filing, ZimVie annual report 10-K simplified, and ZimVie 8-K material events explained in real time, then highlights the exact paragraphs on R&D spend, product recalls, and international approvals. Plain-language summaries, ratio snapshots, and risk red-flags mean ZimVie SEC filings explained simply—no jargon required.
Want transaction insight? Receive instant alerts for ZimVie insider trading Form 4 transactions and track ZimVie executive stock transactions Form 4 before earnings calls. Our coverage extends to:
- Form 4 insider buys & sells with AI commentary on buying patterns
- 10-Q breakdowns that map dental versus spine margins quarter over quarter
- 10-K sections on litigation, FDA risk, and surgeon adoption—already summarized
- Proxy statements outlining ZimVie proxy statement executive compensation benchmarks
- Real-time updates when any new document hits EDGAR
Whether you’re comparing surface-technology R&D outlays, monitoring cash burn ahead of a product launch, or seeking ZimVie earnings report filing analysis, our AI-powered dashboard lets you focus on decisions, not page counts. Experience understanding ZimVie SEC documents with AI—and never miss a ZimVie Form 4 insider transactions real-time update again.
ZimVie Inc. Schedule 13G/A shows that Camber Capital Management LP and Stephen DuBois each report 0 shares beneficially owned of ZIMV common stock, representing 0.0% of the class. The filing identifies Camber Capital Management LP (Delaware) and Stephen DuBois (United States) and lists the issuer address. The statement confirms the securities were not acquired to influence control of the issuer and includes signatures dated 08/27/2025. The filing references an event date of 07/21/2025 requiring the Schedule 13G filing.
ZimVie Inc. is soliciting stockholder votes on a proposed merger that the Board unanimously recommends. The proxy describes a cash merger consideration of $19.00 per share as the proposed per-share merger consideration and discloses a defined go-shop period that expires at midnight New York City time on August 29, 2025 with a possible short extension for certain excluded parties. The proxy states Company common stock trades on NASDAQ under the ticker ZIMV and that, if the merger is completed, Company shares will be delisted and deregistered so current public holders will no longer own equity in the surviving corporation.
The filing includes deal economics and protections: a Company termination fee of $10,125,785 payable to Parent in specified circumstances and a Parent termination fee of $40,503,150 payable to the Company under certain other circumstances. Centerview provided financial analysis including forecasts and non-GAAP measures (Adjusted EBITDA and Unlevered Free Cash Flow) and noted certain balance-sheet items used in valuation work such as $70 million of cash and $221 million of debt as of June 30, 2025.
ZimVie Inc. received an amended Schedule 13G filing showing that Camber Capital Management LP and Stephen DuBois each report beneficial ownership of 1,600,000 shares of ZimVie common stock, representing 5.7% of the class. The holdings are reported with shared voting and shared dispositive power and no sole voting or dispositive power. The filing is an amendment (No. 6) to the Schedule 13G and includes a certification stating the shares were not acquired to change or influence control of the issuer. Addresses for the filers and the issuer's principal executive office are provided, and a Joint Filing Agreement is listed as an exhibit.
FAQ
What is the current stock price of ZIMVIE (ZIMV)?
What is the market cap of ZIMVIE (ZIMV)?
